An unloved health-care stock gets a welcome nod in this AI-obsessed market

Leerink analysts upgraded J&J shares to a buy equivalent due to the company's new drugs. This upgrade is significant in the current AI-obsessed market. The move indicates confidence in J&J's pharmaceutical developments.